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OBJECTIVE—The unfolding of type 1 diabetes involves a
number of steps: defective immunological tolerance, priming of
anti-islet autoimmunity, and destruction of insulin-producing
-cells. A number of genetic loci contribute to susceptibility to
type 1 diabetes, but it is unclear which stages of the disease are
inﬂuenced by the different loci. Here, we analyzed the frequency
of type 1 diabetes–risk alleles among individuals from the
Diabetes Prevention Trial–Type 1 (DPT-1) clinical trial, which
tested a preventive effect of insulin in at-risk relatives of diabetic
individuals, all of which presented with autoimmune manifesta-
tions but only one-third of which eventually progressed to
diabetes.
RESEARCH DESIGN AND METHODS—In this study, 708
individuals randomized into DPT-1 were genotyped for 37 single
nucleotide polymorphisms in diabetes susceptibility loci.
RESULTS—Susceptibility alleles at loci expected to inﬂuence
immunoregulation (PTPN22, CTLA4, and IL2RA) did not differ
between progressors and nonprogressors but were elevated in
both groups relative to general population frequencies, as was
the INS promoter variant. In contrast, HLA DQB1*0302 and
DQB1*0301 differed signiﬁcantly in progressors versus nonpro-
gressors (DQB*0302, 42.6 vs. 34.7%, P  0.0047; DQB*0301, 8.6
vs. 14.3%, P  0.0026). Multivariate analysis of the factors
contributing to progression demonstrated that initial titers of
anti-insulin autoantibodies (IAAs) could account for some (P 
0.0016) but not all of this effect on progression (P  0.00038 for
the independent effect of the number of DQB*0302 alleles). The
INS-23 genotype was most strongly associated with anti-IAAs
(median IAA levels in TT individuals, 60 nU/ml; AT, 121; and AA,
192; P  0.000037) and only suggestively to the outcome of oral
insulin administration.
CONCLUSIONS—With the exception of HLA, most susceptibil-
ity loci tested condition the risk of autoimmunity rather than the
risk of failed immunoregulation that results in islet destruction.
Future clinical trials might consider genotyping INS-23 in addi-
tion to HLA alleles as disease/treatment response modiﬁer.
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T
ype 1 diabetes is an autoimmune disease char-
acterized by destruction of the insulin-producing
-cells in the pancreatic islets. Although its
etiology is not yet understood, strong genetic
and environmental components appear to modulate indi-
vidual disease susceptibility in patients and in animal
models (1). The major histocompatibility complex (MHC)
is the primary genetic determinant of susceptibility to type
1 diabetes in human patients and in the NOD mouse model
(2). In addition, numerous genetic studies in humans and
mice have led to the description of additional susceptibil-
ity loci (IDDM and Idd, respectively), for which the
causative genes have yet to be fully deﬁned in most cases.
The best evidence exists for polymorphisms in the pro-
moter region of the Insulin gene, which may impact
ectopic expression of this locus in the thymus and thereby
modulate immunological tolerance through clonal deletion
of autoreactive thymocytes (3,4). More recently, polymor-
phisms in PTPN22 and CTLA4, two genes key in the
ﬁne-tuning of immune responses, have been associated
with type 1 diabetes (5,6). Several other susceptibility loci
have recently been described in genome-wide association
studies performed in large cohorts (7–9). Although their
identity, biological signiﬁcance, and functional impact
remain to be elucidated, some of these susceptibility loci
appear to be shared across several autoimmune diseases,
suggesting the existence of common regulatory steps
whose dysfunction may lead to autoimmunity (e.g.,
PTPN22 is associated with Graves’ thyroiditis, type 1
diabetes, and Rheumatoid Arthritis, among others).
This complex genetic determinism matches the multiple
steps and checkpoints involved in the pathogenesis of type
1 diabetes. A likely ﬁrst step is the defective induction of
tolerance to self-antigens in immature thymocytes, as
demonstrated in the NOD mouse model (10–12) and
suggested by the impact of INS promoter polymorphisms
in human patients (3,4). A second phase involves activa-
tion of autoreactive cells in the periphery, followed by
lymphocytic inﬁltration of pancreatic islets and the pro-
duction of autoantibodies. Although clinically silent, met-
abolic studies can demonstrate impaired insulin secretion
or altered ﬁrst-phase insulin release after intravenous
glucose challenge (IVGTT) and a ﬂattening of the physio-
logical increase in C-peptide with age (13,14).
This prodromic phase can persist for long periods of
time in mice and in humans; many such pre-diabetic
individuals may never progress to overt diabetes. In the
ﬁnal disease stage, the insulitic inﬁltration results in
massive destruction/functional incapacitation of -cells,
culminating in loss of glycemic control. In animal models,
several factors appear to impact on these checkpoints, in
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2348 DIABETES, VOL. 57, SEPTEMBER 2008particular the timing of self-antigen availability for presen-
tation in the pancreatic lymph nodes, the functionality of
regulatory T-cells, and infectious or related environmental
challenges (rev. in 15,16). In such models, loci that affect
the breakdown of immunological tolerance could be dis-
tinguished from others that control later steps of immu-
noregulation or the aggressivity of the attack on the islets
(10,11,17,18). Whether such checkpoints occur in humans
is unknown, although the long prodromic phase that
precedes onset in at-risk individuals suggests the exis-
tence of similar immunological and genetic steps.
The notion of checkpoints controlled by different medi-
ators raised the hope that pre-diabetic individuals might be
prevented from developing full-blown diabetes by reestab-
lishing tolerance and halting the autoimmune process,
allowing islet regeneration to take place naturally. The
Diabetes Prevention Trial–Type 1 (DPT-1) was set-up with
the speciﬁc goal of identifying anti-islet cytoplasmic anti-
body–positive (ICA
) ﬁrst-degree relatives of type 1 dia-
betic patients at risk for developing type 1 diabetes
themselves and treating them with daily low-dose subcu-
taneous and yearly 4-day intravenous insulin (parenteral
insulin trial) or oral insulin to prevent loss of glycemic
control (19). This study was based on results from NOD
mice (although the protocol used was very different) and
small pilot studies in human patients (20–23). Neither the
parenteral nor the oral insulin treatments resulted in
signiﬁcant modiﬁcation of diabetes incidence, although
post hoc analysis suggested a slight treatment effect in the
subgroup with the highest insulin autoantibody (IAA)
titers at baseline (19,24). In the context of this trial, a large
amount of high-quality longitudinal data was collected,
representing a unique opportunity to study the genetic
factors underlying progression to overt diabetes in anti-
body-positive individuals.
The primary goal of the present study was to gauge the
contribution of type 1 diabetes susceptibility loci to the
transition to full-blown diabetes and thus to elucidate
which stage of the disease is impinged on by such loci. We
genotyped single nucleotide polymorphisms (SNPs) in a
number of known or putative type 1 diabetes susceptibility
loci and also reconsidered the HLA data (19) from the
particular angle of distinguishing progressor from non-
progressor individuals. Beyond the implications for our
understanding of the pathogenic processes in type 1
diabetes, this distinction could have direct clinical conse-
quences, by allowing a more accurate deﬁnition of the risk
of progression in pre-diabetic individuals. Improved pre-
diction would facilitate the design of prevention trials,
and/or deﬁne individuals at particularly high risk for whom
more aggressive therapeutic regimens might be warranted.
RESEARCH DESIGN AND METHODS
Identiﬁcation and randomization of subjects. This study is based on the
data published by the DPT-1 Study Group (19) and Skyler et al. (24). Brieﬂy,
relatives of type 1 diabetic patients were screened for ICAs. In case of a
positive result, IAAs, -cell function, glucose tolerance status, and HLA
genotype were determined. ICA
 and IAA
 individuals with preserved islet
function without HLA DQB1*0602 alleles were deemed to be at intermediate
risk and eligible for randomization to oral insulin or placebo, whereas similar
individuals with an abnormal response to IVGTT were considered high risk
and were randomized in the parenteral insulin trial (intravenous and subcu-
taneous).
In this study, all demographic, clinical, biochemical, and HLA data were
obtained from the original study database after de-identiﬁcation of the
subjects (the 30 April 2003 release of the clinical and phenotypic data, with
antibody data from the 1 November 2004 release). Allele frequencies of
parents of type 1 diabetic patients were retrieved from the Type 1 Diabetes
Genetic Consortium (T1DGC) study (25).
SNP typing. Type 1 diabetes susceptibility SNPs were chosen based on the
available literature (5,7–9,26–32; V.B., C.C., D.M., and C.B., unpublished data).
Starting from ampliﬁed genomic DNA provided by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository,
SNPs were genotyped with ﬂuorogenic allele-discrimination chemistry, as
described previously (11). Primers and probes are described in Supplemen-
tary Table 1 (available in an online appendix at http://dx.doi.org/10.2337/db07-
1736).
Statistical analyses. Categorical variables were analyzed by the 
2 test or
Fisher’s exact test if the counts were less than ﬁve in one of the cells. Survival
differences among groups were assessed by the log-rank test. Cox propor-
tional hazard modeling was applied to multivariate analysis of survival
parameters. Kaplan-Meier survival probability function was used to plot risk
of diabetes onset among subgroups. Impact of SNP genotype classes on IAA
levels was assessed by linear regression on log-transformed initial IAA values.
Data were analyzed with the survival package in the R statistical environment
(http://cran.r-project.org). Because most showed no signiﬁcance, P values
reported here are not corrected for multiple sampling; those tests showing
potential signiﬁcance were reconsidered with a simple Bonferroni correction,
based on the number of SNPs or alleles tested (for HLA alleles, we only
corrected for frequent alleles or haplotypes, ignoring those present in 10
individuals). DPT-1 parental HLA allele frequencies were estimated based on
published transmission disequilibrium of HLA alleles to type 1 diabetes
probands (33–35), according to the following formula: ProAF  ParAF
2 
[ParAF  (1  ParAF)  (%transmission to probands/50%)], where ProAF and
ParAF are the proband and parental allele frequencies, respectively. Hazard
ratios for INS-23 genotype subsets were computed by Cox proportional
modeling. Subgroups of individuals showing maximal treatment efﬁcacy were
identiﬁed by computing survival differences across individual subsets ranked
according to the distribution of log-transformed initial IAA quantiles.
Haplotype reconstruction. CTLA4 haplotypes were reconstructed using
PHASE2.1 (36) and pooling data from progressors and nonprogressors. The
algorithm was run according to the authors’ recommended procedure, and the
output was checked for consistency with different seeds for random numbers
generation.
RESULTS
The goal of this study was to test whether any of the loci
so far associated with susceptibility to type 1 diabetes
might condition progression from the pre-diabetic to the
diabetic state, as opposed to inﬂuencing the autoimmune
deviation that results in pre-diabetes. To that end, DNA
samples and full clinical information were obtained from
individuals randomized into the DPT-1 study. As described
previously (19), 100,000 relatives of type 1 diabetic
patients were screened for autoantibodies (ICA test),
identifying 3,483 positive individuals (Supplementary Fig.
1). To be further considered in the study, ICA
 individuals
had to lack protective HLA-DQA1*0102/DQB1*0602 al-
leles. Individuals with an abnormal IVGTT or insulin-
release assay were eligible for randomization into the
high-risk/parenteral insulin group, whereas subjects with
high IAA titers and preserved IVGTT/oral glucose toler-
ance test were eligible for the medium-risk oral insulin
trial. Four hundred eighteen high-risk and 388 medium-
risk individuals were identiﬁed, who were randomized
between the arms of the study and for whom excellent
follow-up was performed during the years of the DPT-1
trial. Of these, 258 individuals progressed to clinical dia-
betes during the follow-up period. The age distribution
(Supplementary Fig. 2) showed the existence of one group
of individuals (n  638) whose mean age at screening was
3,461 days (9.5 years, range 372–9,628 days) and a second
group (n  70) with a mean age at randomization of 13,597
days (37.3 years, range 10,075–16,340 days), leading to a
bimodal distribution (goodness-of-ﬁt to normality by Kol-
mogorov-Smirnov P  10
70). More importantly, the inci-
dence of progression for the individuals screened after
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we did not include this subgroup to avoid diluting true
genetic effects. The remaining group of 638 individuals
included in our studies encompassed 485 children
screened at age 4,500 days (12.3 years, 76%). In the 258
individuals who progressed to type 1 diabetes, the median
time from screening to diagnosis of type 1 diabetes was 3.7
years (5–95%, 1.2–7 years).
Non-HLA diabetes susceptibility loci and progression.
We ﬁrst addressed the impact of convincingly associated,
non-HLA type 1 diabetes susceptibility polymorphisms on
diabetes progressor/nonprogressor outcome. These included
the INS-23 promoter polymorphism, the PTPN22 R620W
coding-region change, and several 3	-untranslated and in-
tronic polymorphisms in the CTLA4 costimulatory gene (the
CT60 marker and other SNPs, because the causal polymor-
phism in the costimulatory region remains in question). We
also genotyped a number of variants for which the evidence
is more recent or less substantially replicated, including
some discovered in the context of genome-wide association
studies (acknowledging that the low effect of these recently
described variants would likely make the present cohort
underpowered) (5,7–9,26–32,37).
These SNPs were genotyped using ﬂuorogenic PCR with
a success rate of 98.3% (96% of individuals with 93% or
more genotyping success and 100% concordance rate on
repeated genotyping of a handful of markers in all individ-
uals). Because some of these markers have shown strong
population differentiation (e.g., the absence of PTPN22
R620W T in Asian populations), we restricted our analyses
to Caucasian individuals screened at 10,000 days (n 
575), who constitute the majority of subjects recruited into
DPT-1. As depicted in Table 1, no polymorphism showed a
signiﬁcant difference between DPT-1 progressors and non-
progressors, with the exception of a SNP in Lympho-
toxin-
, likely reﬂecting HLA haplotypes (see below). For
a number of SNPs, the allele frequencies in the progres-
sors and in the nonprogressor groups matched well those
usually reported in type 1 diabetic patients. For example,
the PTPN22 R620W T variant is present in 8% of nonaf-
fected U.S. Caucasian populations, 15–20% of type 1 dia-
betic patients, and 15 and 17% of nonprogressor and
TABLE 1
Allele frequencies in DPT-1 participants and comparative cohorts
Chromosome Gene name Polymorphism
Alleles
rs number
Allele counts 0/1/2
0 1 Nonprogressor Progressor
6 Lymphotoxin- 10 G A rs1800683 137/173/39 115/95/17
11 Insulin 23 Hphl T A rs689 16/109/221 7/63/153
1 PTPN22 R620W C T rs2476601 253/86/9 155/66/6
10 IL-2 Ra (CD25) Intron 1 G A rs706778 106/175/64 57/124/45
10 IL-2 Ra (CD25) Intron 1 T C rs3118470 145/160/41 85/115/26
10 IL-2 Ra (CD25) IL-2 Ra region C A rs41295061 307/36/5 194/28/1
10 IL-2 Ra (CD25) IL-2 Ra region T A rs11594656 204/119/20 141/67/13
2 IFIH1 A946T C T rs1990760 43/139/143 25/104/93
1 Fc receptor-like 3 Prom 169 A G rs7528684 99/174/67 74/107/42
6 C6orf118 M256I C A rs510579 144/158/42 88/111/25
5 CAPSL R75Q A G rs1445898 55/184/94 41/103/68
2 CTLA4 Prom 1577 G A rs11571316 129/176/42 90/102/32
2 CTLA4 Prom 318 T C rs5742909 0/60/278 2/34/188
2 CTLA4 T49A G A rs231775 57/175/111 43/115/66
2 CTLA4 3’UTR 6230 (CT60) G A rs3087243 117/181/48 84/105/35
2 CTLA4 JO31 C A rs11571302 101/176/47 74/108/38
2 CD28 Intron 1 C T rs10932017 74/182/90 43/116/64
2 CD28 Intron 1 A T rs2013278 39/145/148 25/98/97
2 CD28 3	UTR G T rs3181113 313/35/0 211/11/1
2 CD28 3	UTR T A rs11681201 22/117/210 12/87/128
2 ICOS Prom 1817 T C rs4452124 263/76/5 182/38/2
2 ICOS Intron 1 C T rs4335928 0/79/269 4/52/170
2 ICOS Intron 1 C T rs4675377 20/146/179 13/92/121
12 VDR BsmI Intron3 T C rs1544410 142/146/56 86/99/38
4 TLR2 S450S T C rs3804100 302/38/1 197/25/2
19 KIR 2DS3 Abs Pres 252/80/0 158/60/0
10 TCF7L2 Intron 3 C T rs7903146 182/134/31 115/90/21
8 SLC30A8 R325W C T rs13266634 187/131/30 116/86/24
10 HHEX HHEX region A G rs7923837 48/160/136 33/112/81
10 HHEX HHEX region G A rs1111875 115/179/54 73/108/45
11 LOC387761 Intron 5 G A rs7480010 189/139/21 115/92/19
11 EXT2 Intron 14 A G rs3740878 200/124/21 119/96/11
12 ERBB2 Intron 7 A C rs2292239 46/191/109 35/100/90
18 PTPN2 Intron 7 T C rs1893217 236/101/8 149/62/14
12 SH2B3 Exon 3 C T rs3184504 85/168/89 54/111/58
12 C12Orf30 Intron 15 A G rs17696736 99/174/72 72/105/47
16 CLEC16A Intron 19 A G rs12708716 160/147/33 100/90/30
*Allele frequencies from the Diabetes in Adolescents and the Very Young (DAVY) study (31). †Allele frequency in Koreans. Abs, absent; MAF,
minor allele frequency; Pres, present.
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tribution was found for the INS-23 A variant (unaffected,
24–32%; type 1 diabetes, 12–18%; nonprogressor, 20%; and
progressor, 17%) and for CTLA4 CT60 G (unaffected, 52%;
type 1 diabetes, 57–63%; nonprogressor, 60%; and progres-
sor, 61%).
Recently described polymorphisms in the TCF7L2,
HHEX, and SLC30A8 loci that predispose to type 2
diabetes (38) were also tested, because islet dysfunction
could precipitate diabetes; no difference in these markers
was observed between progressors and nonprogressors
(Table 1).
Skewed allele frequencies were observed across most
CTLA4 SNPs, in addition to CT60, and in the neighboring
CD28 and ICOS genes. Building on a recent population
genetics study of the CD28 costimulatory locus (28), we
computationally reconstructed haplotypes across CTLA4
in progressor and nonprogressor individuals. As depicted
in Fig. 1, the CTLA4.h1 haplotype carries all high-risk
CTLA4 alleles (CT60 G, 49 G, JO31 G), whereas
CTLA4.h2 regroups most low-risk alleles and is part of a
very homogeneous extended haplotype that spans the
whole costimulatory locus from CD28 to the ICOS pro-
moter region (28). Among DPT-1 individuals, CTLA4.h1
haplotype was enriched in progressors and in nonprogres-
sors, leading to an inversion of the h1-to-h2 frequency ratio
relative to the general population (Fig. 1B). CTLA4.h2
appeared to be more underrepresented in DPT-1 subjects
compared with a U.S. Caucasian control cohort (DCGS)
than any of its individual allelic SNP components (Fig. 1B).
Similarly, a recent study of the costimulatory locus in
patients with celiac disease showed that extended haplo-
types in the region demonstrated stronger association with
disease susceptibility than individual SNPs (39).
Thus, these results suggest that the strongest non-HLA
susceptibility alleles impact type 1 diabetes pathogenesis
at an early stage, conditioning whether tolerance is broken
and autoimmunity sets in, but have less or no inﬂuence on
the course of disease and the probability that this autoim-
munity will lead to terminal -cell destruction.
HLA. Class II genes at the HLA locus represent the
strongest genetic determinant of type 1 diabetes suscepti-
bility (1,2). We chose to analyze the distribution of HLA
alleles and their combinations in a stepwise fashion, to
avoid dilution of effect by multiple genotypic combina-
tions. Tables 2 and 3 represents the distribution of HLA-
TABLE 1
Continued
MAF Control subjects MAF Case subjects MAF
Nonprogressor Progressor OR (95% CI) P value Lit. HapMap CEU DCGS Lit. DCGS
0.36 0.28 1.41 (1.1–1.83) 9.4E–03 0.36 0.34 0.44
0.20 0.17 1.23 (0.9–1.67) 0.22 0.32 0.24 0.28 0.12 0.18
0.15 0.17 1.18 (0.86–1.63) 0.35 0.06–0.15 0.14 0.08 0.15–0.17 0.19
0.44 0.47 1.15 (0.91–1.46) 0.28 00.4–0.45 0.45 0.39* 0.45 0.48*
0.35 0.37 1.09 (0.8–1.39) 0.54 0.32–0.34 0.29 0.25* 0.36 0.38*
0.07 0.07 1.02 (0.63–1.64) 0.96 0.11 0.07
0.23 0.21 1.13 (0.85–1.51) 0.44 0.25 0.21 0.22
0.35 0.35 1.00 (0.78–1.29) 0.97 0.39 0.39 0.35
0.45 0.43 1.11 (0.87–1.41) 0.45 0.45 0.44 0.49 0.44
0.35 0.36 1.03 (0.81–1.33) 0.84 0.35 0.36 0.38
0.44 0.44 1.02 (0.8–1.31) 0.92 0.44 0.39 0.41
0.37 0.37 1.02 (0.8–1.3) 0.94 0.42 0.47 0.46 0.35 0.42
0.09 0.08 1.05 (0.69–1.61) 0.90 0.11 0.06 0.06 0.09 0.08
0.42 0.45 1.12 (0.88–1.42) 0.40 0.43 0.38 0.38 0.29 0.42
0.40 0.39 1.04 (0.82–1.33) 0.79 0.48 0.46 0.47 0.37 0.43
0.42 0.42 1.01 (0.79–1.29) 0.99 0.50 0.49 0.39 0.47
0.48 0.45 1.10 (0.87–1.4) 0.47 0.44 0.42 0.43 0.45
0.34 0.34 1.00 (0.78–1.29) 0.96 0.36 0.23 0.26
0.05 0.03 1.76 (0.92–3.37) 0.11 0.03 0.03 0.04 0.02
0.23 0.24 1.08 (0.82–1.42) 0.64 0.13 0.20 0.15 0.18
0.13 0.09 1.37 (0.93–2.02) 0.14 0.08 0.06 0.08 0.07
0.11 0.13 1.20 (0.84–1.71) 0.38 0.11 0.10 0.10 0.13 0.12
0.27 0.26 1.04 (0.8–1.37) 0.80 0.17 0.18 0.22 0.26
0.38 0.39 1.08 (0.84–1.37) 0.60 0.12–0.25 0.44 0.38 0.12–0.23 0.38
0.06 0.06 1.11 (0.68–1.82) 0.77 0.41† 0.05 0.07 0.39† 0.07
0.12 0.14 1.16 (0.81–1.67) 0.46 0.38 0.32 0.21 0.41
0.28 0.29 1.05 (0.81–1.36) 0.78 0.29 0.25 0.31 0.41 0.30
0.27 0.30 1.11 (0.86–1.45) 0.46 0.30 0.25 0.29 0.25 0.31
0.37 0.39 1.10 (0.86–1.4) 0.50 0.38 0.38 0.37 0.34 0.40
0.41 0.44 1.11 (0.87–1.41) 0.42 0.40 0.44 0.39 0.36 0.41
0.26 0.29 1.15 (0.88–1.5) 0.32 0.30 0.25 0.30 0.34 0.32
0.24 0.26 1.12 (0.85–1.47) 0.48 0.27 0.30 0.27 0.24 0.27
0.41 0.38 1.14 (0.89–1.45) 0.32 0.36 0.30 0.41
0.17 0.20 1.22 (0.9–1.66) 0.22 0.17 0.19 0.21
0.49 0.49 1.01 (0.8–1.29) 0.97 0.49 0.41 0.56
0.46 0.44 1.07 (0.84–1.36) 0.62 0.43 0.35 0.49
0.31 0.34 1.13 (0.88–1.46) 0.37 0.35 0.29 0.31
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DPT-1 trial (association with single DQA alleles showed no
strong signal by themselves or only that expected from
their linkage disequilibrium to DQB alleles; see below).
Because DPT-1 was based on ﬁrst-degree relatives of type
1 diabetic patients, allele frequencies in such families were
bound to be enriched in susceptibility alleles, thus pre-
cluding the use of frequency data in healthy control
subjects as a comparator. Thus, we inferred allele frequen-
cies in the parental population of DPT-1 individuals based
on the HLA allele frequencies of progressors (i.e., type 1
diabetic patients) and the known transmission disequilib-
rium biases of alleles to type 1 diabetes probands (33–35).
As an additional comparison, parental data from the
T1DGC were retrieved (25). In comparison with these
frequencies, which represent a null-hypothesis baseline
for no association, a strong enrichment for DQB1*0201
was observed in progressors and in nonprogressor indi-
viduals, with a weaker trend in DQB*0302. The frequency
of *0201 alleles was the same in both groups, but
DQB1*0302 was enriched in progressors relative to non-
progressors (progressor 42.6% vs. nonprogressor 34.7%;
odds ratio [OR] 1.39; P  0.0047 or P  0.042 after
correcting for multiple sampling). The reverse held true
for DQB1*0301, as this protective allele was signiﬁcantly
less frequent in progressors than in nonprogressors (pro-
gressor 8.6% vs. nonprogressor 14.3%; OR 0.57; P  0.0026,
corrected P  0.023). None of the other alleles appeared
differentially represented in progressors versus nonpro-
gressors, with frequencies comparable with that of the
parental population. These results suggest that type 1
diabetes susceptibility loci in the MHC can impact several
levels of the disease process. Not only can they increase
the probability of autoimmunity, but some haplotypes also
FIG. 1. CTLA4 haplotype representation in DPT-1 individuals. A: Allelic composition of major CTLA4 haplotypes computationally reconstructed
in DPT-1 individuals. For reference, corresponding frequencies in various population groups are indicated (CEPH-HGDP DNA panel [28]). B:
Skewing (OR) of CTLA4 SNPs/haplotype frequency in DPT-1 individuals when compared with ethnicity-matched control cohorts. C: Frequencies
of major CTLA4 haplotypes in DPT-1 and control cohorts.
TABLE 2
HLA DQ alleles and progression to diabetes
N %
Parental
frequency
DQ
Alleles Progressor Nonprogressor Progressor Nonprogressor T1DGC DPT-1 P value* OR (95% CI)*
Median
(y)†
0201 158 245 31.7 31.5 23.2 22.1 0.93 1.01 (0.79–1.29) 12.3
0301 43 111 8.6 14.3 13 13.7 2.59E–03 0.57 (0.39–0.82) 11.9
0302 212 270 42.6 34.7 32.8 28.7 4.70E–03 1.39 (1.11–1.76) 12.6
0303 4 9 0.8 1.2 3.5 1.4 0.54 0.69 (0.21–2.26) 13.1
0402 11 15 2.2 1.9 1.9 2.4 0.73 1.15 (0.52–2.52) 11.2
0501 33 54 6.6 6.9 7.1 7.3 0.83 0.95 (0.61–1.49) 13.1
0502 5 10 1.0 1.3 1.1 — 0.65 0.78 (0.26–2.29) 6.7
0603 11 19 2.2 2.4 3.1 6.5 0.79 0.9 (0.43–1.91) 12.0
0604 16 27 3.2 3.5 4.7 2.6 0.80 0.92 (0.49–1.73) 16.6
*For progressor versus nonprogressor comparisons. †Age of onset in progressors.
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diabetes to diabetes.
We also performed log-rank survival analyses to com-
pare the kinetics of progression to type 1 diabetes of
individuals carrying different HLA alleles. As seen in Fig.
2A, the time–to–type 1 diabetes onset was markedly
TABLE 3
HLA DQ alleles and progression to diabetes among 0302-, 0301-, or 0201-positive individuals
DQ
Alleles
N %
Progressor Nonprogressor Progressor Nonprogressor
P
value* OR (95% CI)*
Median
(y)†
Survival P
value
0302/0201 87 121 48.1% 50.6% 0.60 0.9 (0.61–1.33) 12.07 0.27
0302/0301 21 30 11.6% 12.6% 0.77 0.91 (0.5–1.66) 11.77 0.93
0302/0302 31 31 17.1% 13.0% 0.72 1.39 (0.81–2.38) 13.05 0.05
0302/0402 6 5 3.3% 2.1% 0.44 1.6 (0.48–5.34) 11.04 0.38
0302/0501 18 17 9.9% 7.1% 0.30 1.44 (0.72–2.88) 12.89 0.72
0302/0603 6 11 3.3% 4.6% 0.51 0.71 (0.26–1.96) 11.85 0.74
0302/0604 5 11 2.8% 4.6% 0.33 0.59 (0.2–1.73) 16.36 0.55
0301/0201 5 36 12.5% 35.6% 6.4E–03 0.26 (0.09–0.72) 14.16 5.5E-03
0301/0301 3 10 7.5% 9.9% 0.65 0.73 (0.19–2.84) 11.57 0.58
0301/0501 4 11 10.0% 10.9% 0.88 0.91 (0.27–3.04) 10.72 0.69
0301/0604 5 6 12.5% 5.9% 0.19 2.26 (0.65–7.88) 11.36 0.41
0301/0302 21 30 52.5% 29.7% 0.01 2.62 (1.23–5.56) 11.77 2.8E-03
0201/0201 20 25 14.6% 11.4% 0.38 1.33 (0.71–2.51) 11.23 0.13
0201/0301 5 36 3.6% 16.4% 2.5E–04 0.19 (0.07–0.51) 14.16 2.3E-04
0201/0302 87 121 63.5% 55.0% 0.11 1.42 (0.92–2.21) 12.07 0.29
0201/0402 4 7 2.9% 3.2% 0.89 0.92 (0.26–3.19) 13.71 0.74
0201/0501 8 6 5.8% 2.7% 0.14 2.21 (0.75–6.52) 10.38 0.17
0201/0603 4 3 2.9% 1.4% 0.30 2.18 (0.48–9.87) 12.71 0.50
0201/0604 4 8 2.9% 3.6% 0.71 0.8 (0.24–2.7) 14.09 0.95
*For progressor versus nonprogressor comparisons within a given HLA-DQB positive group. †Age of onset in progressors.
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FIG. 2. Diabetes-free survival and HLA-DQB1 genotypes. Diabetes-free survival in all (n  638) (A) or high-risk (n  295) (B) individuals
screened at age <10,000 days according to their HLA-DQB1*0302 or HLA-DQB1*0301 genotypes. Signiﬁcance of differences in survival is
evaluated by log-rank test. The number of diabetes-free individuals in each category and at distinct time point is shown on the bottom of the
ﬁgure. C: Disease-free survival in individuals screened at age <5,000 or between 5,000 and 10,000 days, stratiﬁed based on their HLA-DQB*0302
or *0301 genotypes.
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dependent manner: Median onset with no *0302 allele was
6.12 years, with a single *0302 allele was 4.71 years, and
with two alleles was 3.65 years (P  2  10
4). Con-
versely, *0301 alleles delayed the progression to overt type
1 diabetes, also in a dose-dependent manner. These ﬁnd-
ings held true when only high-risk individuals were con-
sidered (Fig. 2B). Because it is known that type 1 diabetes
in very young individuals has a speciﬁc genetic architec-
ture (31), we investigated whether DQB alleles impacted
differently on type 1 diabetes incidence based on the age of
the individual, splitting at 5,000 days, which roughly cor-
responds to the pubertal period (Fig. 2C). Individuals
homozygous for DQB*0302 showed an increased inci-
dence of type 1 diabetes and faster kinetics of progression
irrespective of age, whereas the incidence of type 1
diabetes signiﬁcantly dropped after 5,000 days in subjects
lacking *0302. On the other hand, the protective effect of
DQB*0301 was mostly visible in the 5,000 days group.
We then investigated whether combinations of DQ
alleles might differentially impact on progression. Table 3
assesses the representation of the second DQB1 allele
among progressor and nonprogressor individuals already
positive for DQB1*0302, *0301, or *0201. For 0302-positive
individuals, none of the additional alleles had meaningful
impact in either direction (save for the enhancement of
progression in DQB1*0302 homozygotes, consistent with
Fig. 2). On the other hand, the *0301/*0201 combination
was signiﬁcantly underrepresented in progressors,
whether compared with all *0301-positive or with all
*0201-positive individuals (P  0.02 and 0.0016, respec-
tively), suggesting a strong epistatic interaction between
these two alleles (or with the other loci linked to these
variants within the MHC). In contrast, the *0301 allele had
no impact in *0302-positive individuals.
Because nonrandom pairing exists between DQA* and
DQB* alleles in strong linkage disequilibrium, we com-
pared the representation of speciﬁc DQA alleles in
individuals bearing DQB1*0302, *0301, and *0201 (Sup-
plementary Tables 2–4). In individuals heterozygous for
the DQB allele of interest, we used direct DQA allele
counting instead of reconstructing two-loci haplotypes in
double heterozygous (which can only be estimated, be-
cause their true gametic phase is unknown), which pro-
vided sensitivity for DQA-DQB trans-complementation
effects. For DQB1*0302 individuals, the diversity in DQA
allele representation was essentially restricted to het-
erozygous individuals, given the complete linkage disequi-
librium between DQA*0301 and DQB1*0302, and no
signiﬁcant modulation of the progression was observed.
On the other hand, the impact of DQB1*0201 was some-
what modiﬁed by the presence of certain DQA alleles:
DQA*0201 was protective and DQA*0501 promoted pro-
gression but only in DQB*0201 homozygotes. No signiﬁ-
cant impact of DQA was observed in DQB*0301-positive
individuals, although expected trends toward an enrich-
ment of DQA*0301 in progressors and DQA*0501 in non-
progressors were seen.
Treatment effects. Insulin had no signiﬁcant effect over-
all in DPT-1, except for individuals with high anti-IAAs
treated with oral insulin (19,24), but we investigated
whether stratiﬁcation by genotype might show a different
outcome. No difference was found on stratiﬁcation in
DQB1*0302 (Fig. 3) or *0301 (not shown) subgroups. For
the INS-23 polymorphism, a signiﬁcantly enhanced effect
of the oral treatment was seen in individuals heterozygous
for the susceptibility allele; this result should be inter-
preted with caution, however, because it was not repro-
duced in homozygotes, and the nominal degree of
signiﬁcance (P  0.028) would not resist proper correction
for multiple sampling. On the other hand, it is interesting
that the group of INS-23A heterozygotes is that which
shows high IAA titers (see below), and thus likely overlaps
with the high-IAA subgroup which showed some treatment
effect in post hoc analyses (24). Comparative survival
analysis showed very similar hazards ratio for treatment
effect among high-IAA (75
th percentile) and among INS-
23A heterozygotes (OR 0.41 [95% CI 0.2–0.85] and 0.36
[0.15–0.87], respectively).
Type 1 diabetes susceptibility loci and initial autoan-
tibody levels. We then used linear regression to investi-
gate whether any of the genetic markers investigated
showed an association with the level of autoantibodies in
at-risk individuals. Antibody titers at screening were used
for that purpose, instead of summing the counts of positive
antibodies that might mask speciﬁc effects of a given
polymorphism on distinct antibody reactivities (acknowl-
edging that ﬂuctuations in the titers could be observed
over the course of a few months and that the elapsed time
since seroconversion was unknown).
Only the INS, ICOS, and HLA variants showed an
association with IAA titers (Table 4). Genotypes at INS-23
appeared to be the most strongly associated with differ-
ences in baseline IAA levels (P  3.7  10
5,o r1.5 
10
3 after correction for multiple sampling), which is
consistent with previous reports (40–42). The effect was
dominant: individuals heterozygous or homozygous for the
high-risk allele both demonstrated a 2.4-fold increase in
median IAA levels at baseline. A weak association was
observed with DQB1*0302; of note, most of the INS-23
association with IAA titers was found in DQB*0302-nega-
tive individuals. The DQB1*0201 susceptibility allele was
negatively associated with IAA levels. These results sug-
gest complex mechanistic interactions of HLA susceptibil-
ity haplotypes, with a different effect on IAA for the *0302
and *0201 susceptibility alleles.
Redondo et al. (43) observed the same association
between DQB1*0302 and anti-insulin titers but came to the
conclusion that progression to type 1 diabetes in the
DPT-1 cohort was only indirectly correlated with HLA-DQ
status and that the risk of progression to overt diabetes
was actually correlated with the number of autoantibodies
present at randomization, HLA-DQ status being only a
modulator of this number (similarly counting the number
of positive antibodies in our restricted subset also showed
that HLA impacted the progression to type 1 diabetes
mostly in individuals with 0–2 autoantibodies; data not
shown). Because our analysis, which was restricted to the
individuals actually enrolled in the trial, argued for more
complex HLA effects in relation to IAA levels (and not
mere positivity) and type 1 diabetes progression, we
investigated whether these parameters were truly indepen-
dent by building uni- and multivariate Cox proportional
hazards models, including DQB1*0302, *0301, and baseline
IAA levels. As shown in Fig. 4A, baseline IAA and the
number of DQB1*0302 alleles were independently associ-
ated with faster progression toward type 1 diabetes. This
effect of HLA alleles, independent of IAA, is graphically
illustrated by the multivariate Cox analysis of the pre-
dicted time-to-progression for individuals with different
numbers of *0302 alleles, with IAA levels conditioned on
their average value (Fig. 4B).
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bodies, only a weak association with polymorphisms in
CD25 (Supplementary Table 5) was found, compatible
with an additive effect (e.g., median titers 0.185, 0.215, and
0.467 for 0, 1, and 2 rs706778 A alleles; NS when corrected
for multiple sampling).
DISCUSSION
The goal of this study was to identify among known or
suspected type 1 diabetes susceptibility loci those imping-
ing on conversion from the pre-diabetes to the diabetic
state. A clear association was observed with some, but
interestingly not all, HLA class II alleles, an inﬂuence that
went beyond their relation to initial IAA levels. On the
other hand, none of the extra-HLA polymorphisms differed
signiﬁcantly in frequency between progressors versus non-
progressors, a number of them (notably INS-23, PTNP22
R620W, and several CTLA4 markers) showing the typical
elevated frequencies of susceptible alleles in DPT-1 indi-
viduals, irrespective of eventual progression to overt dia-
betes. These results, obtained in individuals 10,000 days
old at screening, still held true when considering the
whole cohort irrespective of age (not shown).
The implication of these results is that most non-HLA
type 1 diabetes susceptibility loci described so far affect
the initial breakdown of immunological tolerance and the
initiation of autoimmunity, rather than the later failures of
immunoregulation that lead to terminal islet destruction. It
is quite plausible that the INS-23A polymorphism would
affect tolerance: Together with the length polymorphism
of the VNTR element further upstream in the INS pro-
moter region, with which it is in tight linkage disequilib-
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FIG. 3. Response to treatment according to HLA-DQB1 and INS-23 genotype. A: All 638 individuals were stratiﬁed according to the number of
HLA-DQB1*0302 alleles and treatment group. Signiﬁcance of differences in survival is evaluated by log-rank test. I, intervention group; P,
placebo/observation. B: Individuals were stratiﬁed based on the number of INS-23A risk alleles.
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and lead to less effective induction of T-cell tolerance to
insulin (3,4). The signiﬁcant association between the INS
susceptibility alleles and higher titers of anti-insulin anti-
bodies, which conﬁrm prior observations associating
INS-23 to IAA incidence in Scandinavian cohorts (40–42),
is also consistent with this notion. PTPN22 encodes a
regulatory phosphatase that modulates T-cell receptor
signaling, and one might hypothesize that the variant
modiﬁes signaling in immature thymocytes and hence
tolerance induction, or the activation of autoreactive T-
cells in the periphery. CTLA4 and CD25, because of their
involvement in regulatory T-cells, might have been thought
a priori to impact on diabetes progression, but this proved
not to be the case. Here also, one might invoke an effect on
T-cell activation at the initiation of autoimmune T-cell
inﬁltration.
HLA. Only HLA-DQ alleles showed a noticeable effect on
type 1 diabetes progression in DPT-1 individuals, partially
in correlation with enhancement of IAA levels, but also
with effects independent of IAA titers. The data conﬁrm an
earlier report of an association of IAA and IA-2 positivity
with the presence of DQB*0302 in Scandinavian type 1
diabetic patients (40). Redondo et al. (43) have also
reported an analysis of HLA haplotypes and genotypes in
relation to autoantibodies and disease progression in the
DPT-1 cohort, albeit with a different strategy that encom-
passed all ICA
 individuals genotyped for HLA (n 
2,046), potentially diluting a genetic effects on progression
in high-risk individuals by the inclusion of many low-risk
individuals, and focused on compound genotypes rather
than individual alleles. These authors also observed the
relationship between progression and DQB1*0302 and
*0301 and found that 57% of DQB*0302-homozygous indi-
TABLE 4
Initial IAA titers and type 1 diabetes susceptibility loci genotypes
Median IAA level by genotype Linear regression P values
Gene Polymorphism
Allele
0
Allele
1 0 1 2 0 and 1 1 and 2 0-1-2
0 vs. 1
and 2
0 and 1
vs. 2
HLA-DQB1 DQB1*0302 Counts 115 183 156 150 180.2 0.034 0.67 1.36E–02
HLA-DQB1 DQB*0201 Counts 176 164 82 169 135 0.044 0.40 1.80E–03
*0302/0201 Abs Pres 137.5 210 0.013
HLA-DQB1 DQB*0301 Counts 168 124 82.5 153 124 0.16 0.714 0.14
Lymphotoxin- 10 G A 153 150 144 150 150 0.75 0.62 0.91
Insulin 23 Hphl T A 61 111 192 104 164.5 3.74E–05 1.05E–04 0.014
PTPN22 R620W C T 145 177 220 150 178 0.37 0.56 0.42
IL-2 Ra (CD25) Intron 1 G A 166 173 103 168 149.5 0.46 0.11 0.80
IL-2 Ra (CD25) Intron 1 T C 161.5 166 120 165 150 0.76 0.30 0.78
IL-2 Ra (CD25) CD25 region C A 148 162.5 87 150 156 0.35 0.88 0.45
IL-2 Ra (CD25) CD25 region T A 146 166.5 98 150 165 0.65 0.43 0.66
IFIH1 A946T C T 124 154.5 149 147 150 0.35 0.56 0.29
Fc receptor-like 3 Prom 169 A G 177.5 141.5 142 151.5 142 0.55 0.94 0.39
C6orf118 M256I C A 153 153 121.5 153 150 0.62 0.63 0.73
CAPSL R75Q A G 131.5 164 141 150 157.5 0.74 0.71 0.31
CTLA4 Prom 1577 G A 183 135 139.5 156 136 0.044 0.21 0.06
CTLA4 Prom 318 T C 18 152.5 150 147 150 0.53 0.33 0.08
CTLA4 T49A G A 148.5 146.5 147 148 147 0.73 0.95 0.49
CTLA4 3	UTR 6230 (CT60) G A 187.5 135 139.5 156 136 0.037 0.22 0.041
CTLA4 JO31 C A 174 146 148 162 146 0.16 0.26 0.24
CD28 Intron 1 C T 131 165.5 141.5 153 159.5 0.63 0.57 0.15
CD28 Intron 1 A T 171 147 147 150 147 0.41 0.56 0.40
CD28 3	UTR G T 157.5 132 540 150 133.5 0.15 0.38 0.11
CD28 3	UTR T A 194 159 141 168 149 0.051 0.07 0.22
ICOS Prom 1817 T C 148 160 203 150 166.5 0.09 0.26 0.13
ICOS Intron 1 C T 63 182.5 141.5 179 153 0.17 0.11 0.42
ICOS Intron 1 C T 382.5 168 135.5 178.5 144.5 4.08E–03 0.044 1.54E–03
VDR BsmI Intron3 T C 153 131 116 150 128 0.87 0.62 0.78
TLR2 S450S T C 150 142 NA 150 142 0.59 — —
KIR 2DS3 Abs Pres 142 150 212 146 164.5 0.66 0.37 0.94
TCF7L2 Intron 3 C T 138 166.5 225.5 149 173.5 0.26 0.24 0.43
SLC30A8 R325W C T 177 147 162.5 147 150 0.63 0.55 0.91
HHEX HHEX region A G 170.5 142 174 149 147 0.98 0.76 0.84
HHEX HHEX region G A 145 181.5 92 156 168 0.97 0.08 0.40
LOC387761 Intron 5 G A 169 131 180 150 133 0.85 0.27 0.76
EXT2 Intron 14 A G 218 231.5 182 218 188 0.17 0.22 0.17
ERBB2 Intron 7 A C 210 120 177 137 141 0.72 0.14 0.19
PTPN2 Intron 7 T C 148 177 126 156 170 0.84 0.80 0.73
SH2B3 Exon 3 C T 169 156 134 160 144.5 0.70 0.86 0.40
C12Orf30 Intron 15 A G 141 177 124 162 157.5 0.52 0.69 0.17
CLEC16A Intron 19 A G 142 159 147.5 149.5 156 0.83 0.92 0.72
UTR, untranslated region.
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pared with only 30% of DQA*0501/DQB*0201 homozygous
(P  3  10
9), yet both genotypes had roughly the same
5-year type 1 diabetes risk when considering their larger
cohort (36 vs. 34%). Redondo et al. (43) concluded that a
relationship between DQB genotypes and number of dif-
ferent autoantibodies at screening could account for these
effects on progression (HLA being irrelevant in individuals
with two or more autoantibodies in their data). The
quantitative survival analysis performed here, based on
measured titers rather than on positive/negative calls,
indicates that the picture is more complex, demonstrating
the limitations of imposing cut-offs when dissecting a
quantitative trait.
The two main susceptibility alleles (DQB1*0302 and
*0201) appear to have different impacts in several re-
spects: *0302 has a direct effect on the risk of progression,
whereas *0201 does not; *0302 has a moderate association
to IAA titers, whereas *0201 does not; *0201 is associated
with higher GAD65 titers (40), whereas *0302 is not; the
impact of *0201 varies with the DQA chain with which it is
paired (in cis or trans), whereas *0302 does not; *0201 has
a strong epistatic interaction with *0301, resulting in
protection of *0201/*0301 heterozygotes, whereas *0302
does not. These observations are consistent with the
notion that *0302 and *0201 provide mechanistically dif-
ferent contributions to disease pathogenesis beyond a
mere modulation of antibody numbers (44–47).
How could HLA be involved at different stages of the
autoimmune pathogenesis? Early effects on tolerance, for
instance by allowing the emergence of a T-cell repertoire
with reactivity against islet peptides (insulin?) might be
expected from their role in selecting T-cells and presenting
self-antigens. In the NOD mouse, the H2
g7 MHC alleles
associated to type 1 diabetes are sufﬁcient to select an
autoreactive repertoire (48). More puzzling is the addi-
tional contribution of DQB1*0302 to further progression.
The enrichment in heterozygous *0302 individuals among
progressors might mirror a multistage process wherein the
initial trigger is ampliﬁed through the presentation of
later-stage “epitope-spreading” antigens, at which *0302
would be particularly efﬁcient. Alternatively, HLA class II
alleles might mediate sensitivity to environmental insults
(e.g., infections or food-borne antigens) after the establish-
ment of a “respectful” insulitis, perhaps tipping the bal-
ance toward immune activation and full-blown islet
destruction. Finally, it is plausible that the negative epista-
sis between DQB1*0201 and DQB1*0301 reﬂects the ability
of MHC class II molecules to form trans-encoded 

dimers. As usual for loci in the HLA region, this discussion
must be cautioned by the strong and complex linkage
disequilibrium structure in the region. Although these
effects may be ascribed to the DQB alleles themselves, it is
also possible that some of them arise from loci in linkage
disequilibrium with the DQB alleles, for instance class I
genes (49).
Pharmacogenetics? Can one, from this analysis, draw
conclusions that would guide the design of other preven-
tion studies, attempting to improve the power of the trials
by using genetic data to reﬁne the selection and better
deﬁne groups of at-risk individuals? Future trials aimed at
evaluating prophylactic interventions might require more
stringent selection criteria against low-risk or protective
HLA genotypes such as DQB*0301 (DQB*0602 was already
an exclusion criteria in DPT-1), which might lead to
artifactual treatment efﬁcacy results if unbalanced among
the study arms (50). The selection of DQB1*0302 individ-
uals would improve the power (power calculations show
that a 20% reduction in total group size could be
achieved by selecting only *0302-positive individuals), but
such a selection would clearly leave out an important
fraction of type 1 diabetic patients.
Although there was no signiﬁcant effect of oral insulin
administration over the entire pool of DPT-1 medium-risk
subjects, post hoc analysis did reveal a slight treatment
effect in the subgroup with the highest initial IAA titers
(19,24). We found that stratiﬁcation by INS-23 genotype
also uncovered a signiﬁcant effect of oral insulin treatment
in heterozygotes (with the limitations on validity of any
such post hoc analysis). Given the association between
INS-23 genotype and IAA levels, one might expect that the
two observations are linked, and subgroup analysis con-
ﬁrmed this to be true. In other trials of oral insulin, it may
be of interest to select candidates on the basis of INS-23
and IAA titers, to test the signiﬁcance and reproducibility
of these observations.
ACKNOWLEDGMENTS
This work has been supported by National Institutes of
Health Grant P01-AI-056299, the William T. Young Chairs
in Diabetes Research, and the Joslin Diabetes and Endo-
crinology Research Center funded cores. The DPT-1 was
supported through cooperative agreements by the NIDDK,
the National Institute of Allergy and Infectious Diseases,
the National Institute of Child Health and Human Devel-
FIG. 4. A: Cox proportional hazard modeling was applied to evaluate
the individual contributions of DQB1 status and initial IAA levels to
progression toward type 1 diabetes. B: Diabetes-free survival accord-
ing to DQB1*0302 status ﬁtted on averaged IAA levels in the Cox
model.
V. BUTTY AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 2357opment, the American Diabetes Association, and the Ju-
venile Diabetes Research Foundation.
We thank Drs. C. Greenbaum and the DPT-1 Publica-
tions Committee for inspiring discussions, the NIDDK
Central DNA Repository for making samples available, W.
Besse for help with genotyping, and all of the DPT-1
participants.
REFERENCES
1. Eisenbarth GS: Update in type 1 diabetes. J Clin Endocrinol Metab
92:2403–2407, 2007
2. Maier LM, Wicker LS: Genetic susceptibility to type 1 diabetes. Curr Opin
Immunol 17:601–608, 2005
3. Vaﬁadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG,
Wickramasinghe S, Colle E, Polychronakos C: Insulin expression in human
thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet
15:289–292, 1997
4. Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C,
Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD: The insulin gene is
transcribed in the human thymus and transcription levels correlated with
allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1
diabetes. Nat Genet 15:293–297, 1997
5. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M,
MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS,
Comings D, Mustelin T: A functional variant of lymphoid tyrosine phos-
phatase is associated with type I diabetes. Nat Genet 36:337–338, 2004
6. Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G,
Rainbow DB, Hunter KMD, Smith AN, Di Genova G, Herr MH, Dahlman I,
Payne F, Smyth D, Lowe C, Twells RCJ, Howlett S, Healy B, Nutland S,
Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C,
Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S,
Allahabadia A, Nithlyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bing-
ley P, Gillespie KM, Undlen DE, Renningen KS, Guja C, Ionescu-Tirgoviste
C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton
DG, Peterson LB, Wicker LS, Todd JA, Gough SCL: Association of the
T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
Nature 423:506–511, 2003
7. The Wellcome Trust Case Control Consortium: Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447:661, 2007
8. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey
R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Haﬂer JP, Zeitels
L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G,
Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington
NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C,
Ionescu-Tirgoviste C, Simmonds MJ, Heward JM, Gough SC, Dunger DB,
Wicker LS, Clayton DG: Robust associations of four new chromosome
regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857–
864, 2007
9. Hakonarson H, Grant SF, Bradﬁeld JP, Marchand L, Kim CE, Glessner JT,
Grabs R, Casalunovo T, Taback SP, Frackelton EC, Lawson ML, Robinson
LJ, Skraban R, Lu Y, Chiavacci RM, Stanley CA, Kirsch SE, Rappaport EF,
Orange JS, Monos DS, Devoto M, Qu HQ, Polychronakos C: A genome-wide
association study identiﬁes KIAA0350 as a type 1 diabetes gene. Nature
448:591–594, 2007
10. Kishimoto H, Sprent J: A defect in central tolerance in NOD mice. Nat
Immunol 2:1025–1031, 2001
11. Zucchelli S, Holler P, Yamagata T, Roy M, Benoist C, Mathis D: Defective
central tolerance induction in NOD mice: genomics and genetics. Immu-
nity 22:385–396, 2005
12. Liston A, Lesage S, Gray DH, O’Reilly LA, Strasser A, Fahrer AM, Boyd RL,
Wilson J, Baxter AG, Gallo EM, Crabtree GR, Peng K, Wilson SR, Goodnow
CC: Generalized resistance to thymic deletion in the NOD mouse: a
polygenic trait characterized by defective induction of Bim. Immunity
21:817–830, 2004
13. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI,
Donaldson D, Harlan DM, Bluestone J, Herold KC: Insulin secretion in type
1 diabetes. Diabetes 53:426–433, 2004
14. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP,
Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS:
Patterns of metabolic progression to type 1 diabetes in the Diabetes
Prevention Trial–Type 1. Diabetes Care 29:643–649, 2006
15. Anderson MS, Bluestone JA: The NOD mouse: a model of immune
dysregulation. Annu Rev Immunol 23:447–485, 2005
16. Tang Q, Bluestone JA: Regulatory T-cell physiology and application to treat
autoimmunity. Immunol Rev 212:217–237, 2006
17. Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D: Genetic
control of diabetes progression. Immunity 7:873–883, 1997
18. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE,
Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R,
Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink
LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P: Interleukin-2 gene
variation impairs regulatory T cell function and causes autoimmunity. Nat
Genet 39:329–337, 2007
19. Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of insulin
in relative of patients with type 1 diabetes mellitus. N Engl J Med
346:1685–1691, 2002
20. Atkinson MA, Maclaren NK, Luchetta R: Insulitis and diabetes in NOD mice
reduced by prophylactic insulin therapy. Diabetes 39:933–937, 1990
21. Bowman MA, Campbell L, Darrow BL, Ellis TM, Suresh A, Atkinson MA:
Immunological and metabolic effects of prophylactic insulin therapy in the
NOD-scid/scid adoptive transfer model of IDDM. Diabetes 45:205–208,
1996
22. Keller RJ, Eisenbarth GS, Jackson RA: Insulin prophylaxis in individuals at
high risk of type I diabetes. Lancet 341:927–928, 1993
23. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG:
Delay of type I diabetes in high risk, ﬁrst degree relatives by parenteral
antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
Diabetologia 41:536–541, 1998
24. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C,
Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E: Effects of oral
insulin in relatives of patients with type 1 diabetes: The Diabetes Preven-
tion Trial–Type 1. Diabetes Care 28:1068–1076, 2005
25. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P,
Mychaleckyj JC, Todd JA, Bonella P, Fear AL, Lavant E, Louey A,
Moonsamy P: HLA DR-DQ haplotypes and genotypes and type 1 diabetes
risk: analysis of the Type 1 Diabetes Genetics Consortium families.
Diabetes 57:1084–1092, 2008
26. Julier C, Hyer RN, Davies J, Merlin F, Soularue P, Briant L, Cathelineau G,
Deschamps I, Otter JI, Froguel P, Boitard C, Bell JI, Lathrop GM:
Insulin-IGF2 region on chromosome 11p encodes a gene implicated in
HLA-DR4-dependent diabetes susceptibility. Nature 354:155–159, 1991
27. Knight JC, Keating BJ, Kwiatkowski DP: Allele-speciﬁc repression of
lymphotoxin-alpha by activated B cell factor-1. Nat Genet 36:394–399, 2004
28. Butty V, Roy M, Sabeti P, Besse W, Benoist C, Mathis D: Signatures of
strong population differentiation shape extended haplotypes across the
human CD28, CTLA4, and ICOS costimulatory genes. Proc Natl Acad Sci U
SA104:570–575, 2007
29. Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C: Toward further
mapping of the association between the IL2RA locus and type 1 diabetes.
Diabetes 56:1174–1176, 2007
30. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C,
Ionescu-Tirgoviste C, Widmer B, Dunger DB, Savage DA, Walker NM,
Clayton DG, Todd JA: A genome-wide association study of nonsynony-
mous SNPs identiﬁes a type 1 diabetes locus in the interferon-induced
helicase (IFIH1) region. Nat Genet 38:617–619, 2006
31. Rodacki M, Svoren B, Butty V, Besse W, Laffel L, Benoist C, Mathis D:
Altered natural killer cells in type 1 diabetic patients. Diabetes 56:177–185,
2007
32. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget
K, Plagnol V, Field S, Atkinson M, Clayton DG, Wicker LS, Todd JA:
Large-scale genetic ﬁne mapping and genotype-phenotype associations
implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet
39:1074–1082, 2007
33. Guja C, Guja L, Nutland S, Rance H, Sebastien M, Todd JA, Ionescu-
Tirgoviste C: Type 1 diabetes genetic susceptibility encoded by HLA DQB1
genes in Romania. J Cell Mol Med 8:249–256, 2004
34. Lie BA, Ronningen KS, Akselsen HE, Thorsby E, Undlien DE: Application
and interpretation of transmission/disequilibrium tests: transmission of
HLA-DQ haplotypes to unaffected siblings in 526 families with type 1
diabetes. Am J Hum Genet 66:740–743, 2000
35. Kawasaki E, Noble J, Erlich H, Mulgrew CL, Fain PR, Eisenbarth GS:
Transmission of DQ haplotypes to patients with type 1 diabetes. Diabetes
47:1971–1973, 1998
36. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype
reconstruction from population data. Am J Hum Genet 68:978–989, 2001
37. Motohashi Y, Yamada S, Yanagawa T, Maruyama T, Suzuki R, Niino M,
Fukazawa T, Kasuga A, Hirose H, Matsubara K, Shimada A, Saruta T:
Vitamin D receptor gene polymorphism affects onset pattern of type 1
diabetes. J Clin Endocrinol Metab 88:3137–3140, 2003
GENETIC DETERMINANTS OF DIABETES PROGRESSION
2358 DIABETES, VOL. 57, SEPTEMBER 200838. Moore AF, Florez JC: Genetic susceptibility to type 2 diabetes and
implications for antidiabetic therapy. Annu Rev Med 59:95–111, 2008
39. Brophy K, Ryan AW, Thornton JM, Abuzakouk M, Fitzgerald AP, McLough-
lin RM, O’Morain C, Kennedy NP, Stevens FM, Feighery C, Kelleher D,
McManus R: Haplotypes in the CTLA4 region are associated with coeliac
disease in the Irish population. Genes Immun 7:19–26, 2006
40. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM, Schafer
JB, Zarghami M, Day HL, Landin-Olsson M, Palmer JP, Janer-Villanueva M,
Hood L, Sundkvist G, Lernmark A, Breslow N, Dahlquist G, Blohme G,
Diabetes Incidence in Sweden Study Group, Swedish Childhood Diabetes
Study Group: Genetics effects on age-dependent onset and islet cell
autoantibody markers in type 1 diabetes. Diabetes Care 26:226–229, 2003
41. Hermann R, Laine AP, Veijola R, Vahlberg T, Simell S, Lahde J, Simell O,
Knip M, Ilonen J: The effect of HLA class II, insulin and CTLA4 gene
regions on the development of humoral beta cell autoimmunity. Diabeto-
logia 48:1766–1775, 2005
42. Nielsen LB, Mortensen HB, Chiarelli F, Holl R, Swift P, de Beaufort C,
Pociot F, Hougaard P, Gammeltoft S, Knip M, Hansen L: Impact of IDDM2
on disease pathogenesis and progression in children with newly diagnosed
type 1 diabetes: reduced insulin antibody titres and preserved beta cell
function. Diabetologia 49:71–74, 2006
43. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP,
Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz D: Speciﬁc human
leukocyte antigen DQ inﬂuence on expression of antiislet autoantibodies
and progression to type 1 diabetes. J Clin Endocrinol Metab 91:1705–1713,
2006
44. Ziegler AG, Standl E, Albert E, Mehnert H: HLA-associated insulin autoan-
tibody formation in newly diagnosed type I diabetic patients. Diabetes
40:1146–1149, 1991
45. Thomson G, Valdes AM, Noble JA, Kockum I, Grote MN, Najman J, Erlich
HA, Cucca F, Pugliese A, Steenkiste A, Dorman JS, Caillat-Zucman S,
Hermann R, Ilonen J, Lambert AP, Bingley PJ, Gillespie KM, Lernmark A,
Sanjeevi CB, Ronningen KS, Undlien DE, Thorsby E, Petrone A, Buzzetti R,
Koeleman BP, Roep BO, Saruhan-Direskeneli G, Uyar FA, Gunoz H,
Gorodezky C, Alaez C, Boehm BO, Mlynarski W, Ikegami H, Berrino M,
Fasano ME, Dametto E, Israel S, Brautbar C, Santiago-Cortes A, Frazer DL,
She JX, Bugawan TL, Rotter JI, Raffel L, Zeidler A, Leyva-Cobian F,
Hawkins BR, Chan SH, Castano L, Pociot F, Nerup J: Relative predisposi-
tional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on
type 1 diabetes: a meta-analysis. Tissue Antigens 70:110–127, 2007
46. Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE,
Sundkvist G, Dahlquist G, Palmer J, Lernmark A: Glutamate decarboxyl-
ase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in
a general population-based study of Swedish children. J Clin Invest
95:1505–1511, 1995
47. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao
D, Erlich HA, Fain PR, Barriga KJ, Norris JM, Rewers MJ, Eisenbarth GS:
Extreme genetic risk for type 1A diabetes. Proc Natl Acad SciUSA
103:14074–14079, 2006
48. Stratmann T, Martin-Orozco N, Mallet-Designe V, McGavern D, Losyev G,
Dobbs C, Oldstone MBA, Yoshida K, Kikutani H, Mathis D, Benoist C,
Haskins K, Teyton L: Susceptible MHC alleles, not background genes,
select an autoimmune T cell reactivity. J Clin Invest 112:902–914, 2003
49. Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE,
Reynolds P, Hardy M, King E, Masters J, Hulme J, Maier LM, Smyth D,
Bailey R, Cooper JD, Ribas G, Campbell RD, Clayton DG, Todd JA, Burton
PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A,
Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ, Todd JA,
Donnelly P, Barrett JC, Burton PR, Davison D, Donnelly P, Easton D,
Evans D, Leung HT, Marchini JL, Morris AP, Spencer CC, Tobin MD,
Cardon LR, Clayton DG, Attwood AP, Boorman JP, Cant B, Everson U,
Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV,
Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T,
Todd JA, Ouwehand WH, Jones RW, McArdle WL, Ring SM, Strachan DP,
Pembrey M, Breen G, St. Clair D, Caesar S, Gordon-Smith K, Jones L,
Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR,
Kirov G, Moskvina V, Nikolov I, O’Donovan MC, Owen MJ, Craddock N,
Collier DA, Elkin A, Farmer A, Williamson R, McGufﬁn P, Young AH, Nicol
FI, Ball SG, Balmforth AJ, Barrett JH, Bishop DT, Iles MM, Maqbool A,
Yuldasheva N, Hall AS, Braund PS, Burton PR, Dixon RJ, Mangino M,
Stevens S, Tobin MD, Thompson JR, Samani NJ, Bredin F, Tremelling M,
Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA,
Forbes A, Lewis CM, Onnie CM, Prescott NJ, Sanderson J, Mathew CG,
Barbour J, Khalid MM, Todhunter CE, Mansﬁeld JC, Ahmad T, Cummings
FR, Jewell DP, Webster J, Brown MJ, Clayton DG, Lathrop GM, Connell J,
Dominiczak A, Samani NJ, Braga CA, Burke B, Dobson R, Gungadoo J, Lee
KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulﬁeld M,
Farrall M, Barton A, Bruce IN, Donovan H, Eyre S, Gilbert PD, Hider SL,
Hinks AM, John SL, Potter C, Silman AJ, Symmons DP, Thomson W,
Worthington J, Clayton DG, Dunger DB, Nutland S, Stevens HE, Walker
NM, Widmer B, Todd JA, Frayling TM, Freathy RM, Lango H, Perry JR,
Shields BM, Weedon MN, Hattersley AT, Hitman GA, Walker M, Elliott KS,
Groves CJ, Lindgren CM, Rayner NW, Timpson NJ, Zeggini E, McCarthy
MI, Newport M, Sirugo G, Lyons E, Vannberg F, Hill AV, Bradbury LA,
Farrar C, Pointon JJ, Wordsworth P, Brown MA, Franklyn JA, Heward JM,
Simmonds MJ, Gough SC, Seal S, Stratton MR, Rahman N, Ban M, Goris A,
Sawcer SJ, Compston A, Conway D, Jallow M, Newport M, Sirugo G,
Rockett KA, Kwiatkowski DP, Bryan C, Bumpstead SJ, Chaney A, Downes
K, Ghori J, Gwilliam R, Hunt SE, Inouye M, Keniry A, King E, McGinnis R,
Potter S, Ravindrarajah R, Whittaker P, Withers D, Deloukas P, Leung HT,
Nutland S, Stevens HE, Walker NM, Todd JA, Easton D, Clayton DG,
Burton PR, Tobin MD, Barrett JC, Evans D, Morris AP, Cardon LR, Cardin
NJ, Davison D, Ferreira T, Pereira-Gale J, Hallgrimsdottir IB, Howie BN,
Marchini JL, Spencer CC, Su Z, Ying TY, Vukcevic D, Donnelly P, Bentley
D, Brown MA, Cardon LR: Localization of type 1 diabetes susceptibility to
the MHC class I genes HLA-B and HLA-A. Nature 450:887–892, 2007
50. Skyler JS: Prediction and prevention of type 1 diabetes: progress, prob-
lems, and prospects. Clin Pharmacol Ther 81:768–771, 2007
V. BUTTY AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 2359